The U.S. government will give pharmaceutical company Moderna $176 million for a High Path Avian Flu vaccine, according to Reuters.
It uses the same technology as the COVID-19 vaccine, and Moderna began development and testing it last year on adults.
“mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic,” said Moderna CEO Stephane Bancel.
So far, four agriculture workers have contracted the virus since 2022.
Related Stories
Eric Weaver with UNL joins us to share about a promising new HPAI vaccine, early test results, next steps in development, and its potential impact on the livestock industry.
$2 million project tests fogging system to stop the virus in poultry facilities
More than 15 million birds were affected by bird flu, but fewer outbreaks are helping bring egg prices down
Bigger flocks are rebuilding egg and poultry supply.
As spring migration ramps up, USDA officials warn farmers about rising bird flu risks and urge stronger biosecurity measures. Resources are available through APHIS to help protect livestock.
APHIS Veterinary Medical Officer Dr. Chelsey Shiveley discusses USDA’s biosecurity resources available to poultry producers ahead of spring migration, increasing the risk of Highly Pathogenic Avian Influenza (HPAI) threatens commercial flocks.
